Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer-Reference-Cited by-同舟云学术

Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer

Published:2013-02 Issue: Volume:29 Page:17-24
ISSN:1089-8603
Container-title:Nitric Oxide
language:en
Short-container-title:Nitric Oxide

Author:

Huerta-Yepez Sara,Baritaki Stavroula,Baay-Guzman Guillermina,Hernandez-Luna Marco A.,Hernandez-Cueto Angeles,Vega Mario I.,Bonavida Benjamin

Publisher

Elsevier BV

Subject

Cancer Research,Clinical Biochemistry,Physiology,Biochemistry

Reference30 articles.

1. Anti-cancer drug resistance. understanding the mechanisms through the use of integrative genomics and fucntional RNA interference;Tan;Eur. J. Cancer,2010

2. Notch: a key regulator of tumor angiogenesis and metastasis;Garcia;Histol. Histopathol.,2012

3. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes;Shen;Pharmacol. Rev.,2012

4. Apoptosis: a relevant tool for anticancer therapy;Russo;Ann. Oncol.,2006

5. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent;Katsman;Drug Resist. Updat.,2007

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the significance of inducible nitric oxide synthase: Its impact on cancer progression and clinical implications;Cancer Letters;2024-06

2. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1;Cancers;2024-03-21

3. Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy;Cancers;2024-01-23

4. Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products via the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic Implications;Antioxidants & Redox Signaling;2023-11-01

5. Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions;Cancers;2023-07-05